MET tyrosine kinase inhibitor PF-02341066
A drug used to treat advanced non-small cell lung cancer that has a mutated (changed) form of a gene called anaplastic lymphoma kinase (ALK). It is also being studied in the treatment of other types of cancer. MET tyrosine kinase inhibitor PF-02341066 blocks the protein made by the mutated ALK gene. Blocking this protein may stop the growth and spread of cancer cells. MET tyrosine kinase inhibitor PF-02341066 may also prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent. Also called crizotinib, PF-02341066, and Xalkori.